NSCLC, EGFR activating mutation, osimertinib, predictive factors, Liquid biopsy, 18F-FDG PET/CT
non-small cell lung cancer, radiotherapy, durvalumab, oligorecurrence, recurrence pattern, chemoradiotherapy, salvage therapy, SBRT, PACIFICnon-small cell lung cancer, radiotherapy, durvalumab, oligorecurrence, recurrence pattern, chemoradiotherapy
database, molecular records, clinical records, NSCLC